Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer

Autor: Mesut Seker, Tarik Demir, Rabia Sevda Celik, H. Mehmet Turk, Tuba Baydas, Altay Aliyev, Ezgi Coban, Abdurrahim Kocyigit
Přispěvatelé: ŞEKER, Mesut
Rok vydání: 2020
Předmět:
Adult
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Necrosis
Paclitaxel
Anthracycline
medicine.medical_treatment
Breast Neoplasms
03 medical and health sciences
Cytokeratin
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
Predictive Value of Tests
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
medicine
Humans
Anthracyclines
Breast
Prospective Studies
Prospective cohort study
Mastectomy
Aged
Chemotherapy
Turk H.
Aliyev A.
Celik R.
Seker M.
Coban E.
Demir T.
Baydas T.
Kocyigit A.
-Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.-
Current problems in cancer
ss.100497
2019
Keratin-18
business.industry
Middle Aged
Prognosis
medicine.disease
Neoadjuvant Therapy
Peptide Fragments
Regimen
Treatment Outcome
030104 developmental biology
chemistry
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
medicine.symptom
business
Zdroj: Current Problems in Cancer. 44:100497
ISSN: 0147-0272
DOI: 10.1016/j.currproblcancer.2019.06.009
Popis: M30 and M65 levels reflect tumor cell activity in patients with epithelial cancer. Cytokeratin 18 is one of the cell skeletal elements. M30 is a apoptotic marker of cytokeratin 18. M65 levels are both an apoptosis and a necrosis marker. The aim of our study was to determine the predictive value of M30 and M65 levels in neoadjuvant treatment of breast cancer.In this prospective study, 41 patients with breast cancer who underwent neoadjuvant chemotherapy were included. Following 4 cycles of chemotherapy with anthracycline containing regimen, patients received paclitaxel treatment for 12 weeks. Blood was collected from the patients before chemotherapy and on day 21, after the 2nd, 4th, and 8th cycles. M30 and M65 levels were measured with the ELISA method.While there was an increase in M30 and M65 levels at the 4th cycle (P0.05), levels were decreased after the 8th cycle. In addition, there was no significant relationship among M30, M65 levels, and prognostic factors such as ER, PR, c-Erb-2, Ki-67, pathologic-T, pathologic-N, and chemotherapy responses.M30 and M65 levels are not of predictive values of response to breast cancer patients receiving neoadjuvant chemotherapy. Nevertheless, M30 and M65 levels increased when patients kept receiving anthracycline containing chemotherapy.
Databáze: OpenAIRE
Externí odkaz: